Sepsis Alliance Symposium: Healthcare Associated Infections 2024
Includes a Live Web Event on 12/12/2024 at 8:00 AM (PST)
Description:
Date: December 12, 2024
Time: 10:00 am - 3:00 pm ET / 7:00 am - 12:00 pm PT
Healthcare-associated infections (HAIs) are the most common challenge in hospital settings, posing significant risks for both patients and healthcare providers. According to the Centers for Disease Control and Prevention (CDC), one in every 31 hospital patients contracts at least one HAI daily, leading to substantial financial burdens for healthcare organizations. The risk of HAIs escalating into sepsis underscores the critical need for effective prevention measures.
Healthcare professionals must prioritize the identification and implementation of strategies to improve performance and outcomes in preventing HAIs and sepsis across all departments and specialties.
Sepsis Alliance is hosting the 2024 Sepsis Alliance Symposium: Healthcare-Associated Infections to continue our mission and further the idea that infection prevention is sepsis prevention. This engaging virtual event will take place on December 12, 2024, and will delve into essential topics surrounding HAIs. Attendees will gain access to cutting-edge clinical insights and the latest recommendations for preventing and treating infections. This half-day symposium aims to highlight the importance of HAI prevention in clinical practice, ultimately striving to improve patient outcomes and reduce the incidence of sepsis.
Topics covered will include:
- Healthcare-associated C-Diff
- Role of gut microbiome in HAI prevention
- Catheter-associated urinary tract infections (CAUTI)
- Central line-associated bloodstream infections (CLABSI)
- HAI surveillance: Past, present, and future
- Preventing healthcare-associated infections in surgical patients
Learning Objectives:
At the end of the activity, the learner should be able to:
- Demonstrate increased knowledge relating to maintaining a compliant and effective infection prevention and control program in the healthcare setting;
- Describe examples of infection prevention and control evidence-based best practices and recommendations;
- Propose innovative approaches, protocols, tools and documentation for limiting healthcare-associated infections.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Symposium Supporters:
Sepsis Alliance gratefully acknowledges the support provided for this symposium by the following sponsors:
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 3.6 contact hours.
Other healthcare professionals will receive a certificate of attendance for 3.0 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
Welcome & Opening Remarks
Time: 10:00 - 10:10 AM ET
Session 1
Time: 10:10 - 10:40 AM ET
More information to come.
Session 2
Time: 10:40 - 11:10 AM ET
More information to come.
Sponsor Session 1
BD Sponsored Session: Clinical Burden of Hospital Onset Bacteremia and Fungemia (HOB)
Time: 11:25 - 11:40 AM ET
Hospital Onset Bacteremia & Fungemia (HOB) is a new metric proposed by the CDC for National Healthcare Safety Network (NHSN) volunteer reporting. This sponsored presentation will delve into recent research papers that elucidate the differences between HOB and Central Line-associated Bloodstream Infection (CLABSI), the impact of urine sources on Catheter Associated Urinary Tract Infections (CAUTI) and non-catheter Hospital Onset UTIs contributing to HOB, the burden of Surgical Site Infections (SSI) associated with HOB, and the overall clinical and health economic significance of HOB.
Session 3
Time: 11:40 AM - 12:10 PM ET
More information to come.
Sponsor Session 2
BD Sponsored Session: The Impact of Drug-Resistant Infections in the Cancer Community
Time: 12:10 - 12:40 PM ET
Nearly 100 years ago, scientists handed the world a new miracle drug: antibiotics. This revolutionized healthcare, improving the length and quality of our lifespans. Modern medicine has been built on the bedrock of being capable of controlling infections while treating aggressive disease. We stand on the precipice of losing this ability, as antimicrobial resistance (AMR) threatens to overwhelm our antibiotic and antifungal supply. Nowhere is this more concerning than in the cancer community. This sponsored presentation will review current literature analyzing the impact of AMR on the cancer community and will provide an overview of suggested actions we can take to reduce the risk of drug-resistant infections.
Session 4
Time: 12:40 - 1:10 PM ET
More information to come.
Session 5
Compendium of Strategies to Prevent CAUTIs: 2022 Updates
Time: 1:25 - 1:55 PM ET
This presentation offers a comprehensive overview of the latest methods to prevent catheter-associated urinary tract infections (CAUTIs). Recent changes and additions to the CAUTI Compendium, providing participants with updated strategies to minimize infection risks, will be covered. Attendees will also learn how to incorporate diagnostic and antimicrobial stewardship into their CAUTI prevention practices effectively. Additionally, the differences between infectious and noninfectious harms linked to CAUTIs will be explored, equipping healthcare professionals with the knowledge to improve patient outcomes.
Sponsor Session 3
CorMedix Sponsored Session: Reducing the Risk of Catheter Related Blood Stream Infections in Hemodialysis Patients
Time: 1:55 - 2:10 PM ET
In this sponsored session, learn about the risks of catheter related blood stream infections in hemodialysis patients. Opportunities for prevention will also be discussed, including the clinical data for a recent FDA-approved catheter lock solution. The presenter will cover ways for healthcare teams to work together to improve patient outcomes.
Sponsor Session 4
Wolters Kluwer Sponsored Session
Time: 2:10 - 2:25 PM ET
More information to come.
Session 6
Strategies for Preventing C. difficile Infections in Hospitals
Time: 2:25 - 2:55 PM ET
This presentation will explore the current landscape of C. difficile infections in U.S. hospitals, emphasizing the urgency of addressing this persistent healthcare challenge. Attendees will gain insights into the most effective infection prevention strategies, including well-established and emerging practices. The session will also address the complexities and ongoing debates around additional preventative measures, offering a comprehensive understanding of how hospitals can enhance patient safety and reduce infection rates.
Closing Remarks: Key Takeaways
Time: 2:55 - 3:00 PM ET
| Time (ET) | Session Title | Presenter |
|---|---|---|
| 10:00-10:10 | Welcome and Opening Remarks | |
| 10:10-10:40 | Session 1: More information to come | |
| 10:40-11:10 | Session 2: More information to come | |
| 11:10-11:25 | Break | |
| 11:25-11:40 | BD Sponsored Session: Clinical Burden of Hospital Onset Bacteremia and Fungemia (HOB) | Kalvin Yu, MD, FIDSA
Vice President of Medical Affairs, North America, BD Samantha Bastow, PharmD, MBA Associate Director, Clinical Integration, Medical Affairs, US Region, BD |
| 11:40-12:10 | Session 3: More information to come | |
| 12:10-12:40 | BD Sponsored Session: The Impact of Drug-Resistant Infections in the Cancer Community | Diane Flayhart, MS Director, Global Public Health BD |
| 12:40-1:10 | Session 4: More information to come | |
| 1:10-1:25 | Break | |
| 1:25-1:55 | Session 5: Compendium of Strategies to Prevent CAUTIs: 2022 Updates | Payal Patel, MD, MPH, FIDSA System-Wide Medical Director of Antimicrobial Stewardship, Associate Professor Intermountain Health |
| 1:55-2:10 | CorMedix Sponsored Session: Reducing the Risk of Catheter Related Blood Stream Infections in Hemodialysis Patients | Anil Agarwal, MBBS, MD, FACP, FASN, FISN, FNKF, FASDIN Professor of Medicine University of California San Francisco |
| 2:10-2:25 | Wolters Kluwer Sponsored Session: More information to come | |
| 2:25-2:55 | Session 6: Strategies for Preventing C. difficile Infections in Hospitals | Larry K. Kociolek, MD, MSCI, FSHEA, FPIDS Vice President, System Preparedness, Prevention, and Response; Attending Physician, Division of Infectious Diseases; Ann & Robert H. Lurie Children’s Hospital of Chicago |
| 2:55-3:00 | Closing Remarks: Key Takeaways |
Anil Agarwal, MBBS, MD, FACP, FASN, FISN, FNKF, FASDIN
Professor of Medicine
University of California San Francisco
Anil K. Agarwal, MD, FACP, FASN, FISN, FNKF, FASDIN, is the Chief of Medicine at Veterans Affairs Central California Health Care System at Fresno, California and a Professor of Clinical Medicine at The University of California San Francisco at Fresno. Dr. Agarwal is a passionate clinician, educator, and author, and is an internationally recognized expert in hypertension, chronic kidney disease, dialysis, anemia, mineral bone disorders, and vascular access. He has conducted over 50 clinical trials, developed protocols, and published results of studies. He is a frequently sought speaker nationally and internationally. He serves and chairs many committees and boards, and also serves as editor and reviewer for several medical journals.
Samantha Bastow, PharmD, MBA
Associate Director, Clinical Integration, Medical Affairs, US Region
BD
As the Associate Director of Clinical Integration in Medical Affairs at BD, Samantha Bastow, PharmD, MBA, is responsible for overseeing and managing both the clinical and administrative aspects of the medical division of business. This includes innovation and new product and business development, lifecycle clinical evidence generation, market shaping and development, and safety and compliance. Prior to BD, she served as the Director of Clinical Pharmacy Services at the University of Chicago Medical Center, where she led inpatient and emergency clinical pharmacy service lines, including antimicrobial stewardship, in addition to formulary management, clinical decision support, business development, research and academic responsibilities. Samantha holds a PharmD from Palm Beach Atlantic University and an MBA with a specialization in data analytics from the University of Illinois. She completed a PGY1 residency at Sarasota Memorial Hospital followed by an emergency medicine pharmacy residency at Boston Medical Center.
Diane Flayhart, MS
Director, Global Public Health
BD
As a Director in Global Public Health at BD, Diane Flayhart, MS, is responsible for leading global policy and advocacy efforts on antimicrobial resistance. She works with global stakeholders in a collaborative and programmatic approach to strengthen healthcare systems. She also leads efforts for the Antimicrobial Resistance Fighter Coalition, a global organization that seeks to increase awareness of drug-resistant infections and encourage action. Prior to joining BD, Diane managed the clinical microbiology laboratory at The Johns Hopkins Hospital.
Larry K. Kociolek, MD, MSCI, FSHEA, FPIDS
Vice President, System Preparedness, Prevention, and Response
Ann & Robert H. Lurie Children’s Hospital of Chicago
Larry K. Kociolek, MD, MSCI, FSHEA, FPIDS, is an Attending Physician in the Division of Pediatric Infectious Diseases and Vice President of System Preparedness, Prevention, and Response at Ann & Robert H. Lurie Children’s Hospital of Chicago, and he is an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. At Lurie Children’s, Dr. Kociolek leads preparedness, prevention, and response efforts for all hazards, including emerging pathogens. He serves as site PI for the HRSA-funded Pediatric Pandemic Network.
Dr. Kociolek is the Principal Investigator of several NIH-funded translational research studies focused on the epidemiology and prevention of healthcare-associated and other high-consequence infections in children, particularly C. difficile infection and COVID-19. He serves on the Pediatric Leadership Council for the Society for Healthcare Epidemiology of America (SHEA) whose goal is to lead national advocacy, research, and education efforts for prevention of healthcare-associated infections in children. Through SHEA, he has led an international group of experts to define best practices for the prevention of C. difficile infections in adults and children in acute care hospitals.
Payal Patel, MD, MPH, FIDSA
System-Wide Medical Director of Antimicrobial Stewardship, Associate Professor
Intermountain Health
Payal Patel, MD, MPH, FIDSA, is an associate professor at Intermountain Health and the systemwide medical director of antimicrobial stewardship. She is an infectious diseases physician and is passionate about improving patient safety and antimicrobial stewardship. Dr. Patel serves on the Presidential Advisory Council on Combatting Antibiotic Resistance and has worked with developing antimicrobial stewardship programs in several countries including India, Japan, and Italy. She is the lead author on the most recent CAUTI compendium.
Kalvin Yu, MD, FIDSA
Vice President of Medical Affairs, North America
BD
As the Vice President of Medical Affairs for North America, Kalvin Yu, MD, FIDSA, is responsible for providing medical and scientific leadership and operationally viable BD Solutions with clinicians and healthcare systems across the United States. Before BD, Dr. Yu was the Chief Integration Officer and Chief of Infectious Diseases at Southern California Kaiser Permanente, where he implemented multidisciplinary quality and patient safety programs among different hospitals and service lines. Dr. Yu trained at the UCLA School of Medicine and was a former Associate Professor of Infectious Disease and Global Public Health at NYU. Published research areas include patient outcomes, readmissions, and quality metric benchmarking. He was a member of the CDC Antibiotic Utilization workgroup, and has been an invited speaker at IDSA, SHEA, Pew Trusts, and Capitol Hill in Washington D.C. Dr. Yu was nominated and inducted as a Fellow in the Infectious Diseases Society of America in 2020.
Please feel free to download, print, display, or share the flyer linked below. It contains a QR code that can be used to register for this symposium.